Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04050670 · ClinicalTrials.gov registry record · Phase 1
A Study of Tirzepatide at Different Injection Sites in Participants With Different Body Sizes
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 54
- Enrollment target
NCT04050670 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 54 participants.
The verdict
NCT04050670, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 54 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the amount of tirzepatide that gets into the blood stream and how long it takes the body to get rid of it, when injected under the skin of the upper arm and thigh compared to the abdomen. The study will be conducted in healthy males and females with different body sizes. The tolerability of tirzepatide will be evaluated and information about any side effects experienced will be collected. For each participant, the study will last about 20 weeks, including screening.
Interventions
- DRUG Tirzepatide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2019-09-13 |
| Est. Completion | 2020-04-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04050670
The ClinicalTrials.gov registry entry for NCT04050670 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tirzepatide is the first listed.
NCT04050670 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04050670 about?
NCT04050670 is a clinical study titled "A Study of Tirzepatide at Different Injection Sites in Participants With Different Body Sizes". The purpose of this study is to compare the amount of tirzepatide that gets into the blood stream and how long it takes the body to get rid of it, when injected under the skin of the upper arm and thigh compared to the abdomen. The study will be conducted in healthy males and females with different ...
What is the current status of trial NCT04050670?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2019-09-13. Estimated completion is 2020-04-03.
What interventions are being tested in trial NCT04050670?
The interventions under investigation include: Tirzepatide (DRUG).
Who is sponsoring clinical trial NCT04050670?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.